Pharming Group (PHAR) Stock Price, News & Analysis

Company Overview

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe. RUCONEST represents the first recombinant C1 inhibitor therapy, offering an alternative to plasma-derived treatments and addressing key safety and supply concerns associated with conventional sources. Pharming continues to support RUCONEST through lifecycle management initiatives and expanded patient access programs.

Beyond its marketed product, Pharming’s research and development pipeline includes additional indications for C1 esterase inhibitor in prophylactic HAE treatment and novel programs targeting other rare and genetic disorders. Preclinical efforts leverage the same transgenic expression platform to explore therapies for conditions such as alpha-1 antitrypsin deficiency and metabolic disorders. Strategic collaborations and licensing agreements underpin the company’s approach to expanding its portfolio and reaching underserved patient populations.

Pharming Group serves patients and partners across Europe, North America, Latin America and Asia-Pacific through a combination of direct commercial operations and regional partnerships. The company is led by Chief Executive Officer Sijmen de Vries, whose experience in biotechnology and global product commercialization supports Pharming’s mission to deliver life-transforming therapies to individuals affected by rare diseases.

Key Stats

• Today's Range: $16.32 to $16.74
• 50-Day Range: $14.51 to $17.80
• 52-Week Range: $8.60 to $21.34
• Volume: 2,548 shs
• Average Volume: 23,584 shs
• Market Capitalization: $1.15 billion
• P/E Ratio: 1,628.00
• Dividend Yield: N/A
• Price Target: $38.33
• Consensus Rating: Moderate Buy

Pharming Group Stock Analysis - MarketRank™

Pharming Group scored higher than 86% of companies evaluated by MarketBeat, and ranked 67th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pharming Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Pharming Group has a consensus price target of $38.33, representing about 135.5% upside from its current price of $16.28.

Amount of Analyst Coverage

Pharming Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 15.79%

Earnings Growth

Earnings for Pharming Group are expected to grow by 15.79% in the coming year, from $0.38 to $0.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pharming Group is 1,628.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.36.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pharming Group is 1,628.10, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.27.

Price to Book Value per Share Ratio

Pharming Group has a P/B Ratio of 4.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Pharming Group has been sold short.

Short Interest Ratio / Days to Cover

Pharming Group has a short interest ratio ("days to cover") of 0.65, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pharming Group has recently decreased by 28.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharming Group does not currently pay a dividend.

Dividend Growth

Pharming Group does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.53

News Sentiment

Pharming Group has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Pharming Group this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for PHAR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Pharming Group to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pharming Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.07% of the stock of Pharming Group is held by insiders.

Percentage Held by Institutions

0.03% of the stock of Pharming Group is held by institutions.

PHAR Stock Analysis - Frequently Asked Questions

How have PHAR shares performed this year?

Pharming Group's stock was trading at $17.67 at the beginning of 2026. Since then, PHAR stock has decreased by 7.9% and is now trading at $16.28.

How were Pharming Group's earnings last quarter?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) issued its quarterly earnings data on Thursday, March, 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by $0.08. The company earned $106.50 million during the quarter, compared to analyst estimates of $111.76 million. Pharming Group had a net margin of 0.71% and a trailing twelve-month return on equity of 1.08%.
Read the conference call transcript.

When did Pharming Group IPO?

Pharming Group (PHAR) raised $0 in an initial public offering on Wednesday, December 23rd 2020. The company issued 899,802 shares at $0.00 per share.

Who are Pharming Group's major shareholders?

Top institutional shareholders of Pharming Group include Silverberg Bernstein Capital Management LLC (0.06%) and SmartHarvest Portfolios LLC (0.02%).

How do I buy shares of Pharming Group?

Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pharming Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharming Group investors own include Pharming Group (PHGUF), Meta Platforms (META), NVIDIA (NVDA), Applied DNA Sciences (APDN), Costco Wholesale (COST).

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/07/2026
• AGM 2026: 5/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHAR
• CIK: 1828316
• Web: www.pharming.com
• Phone: 31-71-524-7400
• Fax: N/A
• Employees: 280
• Year Founded: 1988

Price Target and Rating

• Average Price Target for Pharming Group: $38.33
• High Price Target: $41.00
• Low Price Target: $37.00
• Potential Upside/Downside: +136.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.01
• Trailing P/E Ratio: 1,624.00
• Forward P/E Ratio: 42.74
• P/E Growth: N/A
• Net Income: $2.85 million
• Net Margins: 0.71%
• Pretax Margin: 3.42%
• Return on Equity: 1.08%
• Return on Assets: 0.59%

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 2.59
• Quick Ratio: 2.03

Sales & Book Value

• Annual Sales: $376.13 million
• Price / Sales: 3.05
• Cash Flow: $0.20 per share
• Price / Cash Flow: 81.72
• Book Value: $3.95 per share
• Price / Book: 4.11

Miscellaneous

• Outstanding Shares: 70,620,000
• Free Float: 69,163,000
• Market Cap: $1.15 billion
• Optionable: Not Optionable
• Beta: 0.04